CMS Solicits Ideas To Improve Part D: An Opening For Co-Pay Reform And Shaping Priorities
Executive Summary
The US Medicare agency signals interest in making administrative changes to the Part D drug insurance program in the coming years. That may be an opening for the pharmaceutical industry to push for new approaches to cost-sharing – but it is also an opportunity for plans to try to shape the evolution of Part D in the Trump administration.
You may also be interested in...
Part D Reforms: Concerns With Specialty Cost Sharing, Merging Part B Coverage Raised
BIO comments respond to the Centers for Medicare and Medicaid Services' call for input on ways to improve the Medicare Part D program.
Best Defense Is Good Offense: PhRMA Wants PBMs To 'Share The Savings'
PhRMA ad campaign targets US payer practice of using drug rebate dollars for general premium and cost sharing reductions and not to lower the cost of specific prescription fills.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.